TM Owner Eli Lilly
Retatrutide (Investigational) Investigational Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Retatrutide (Investigational) is NOT an approved or marketed medicine anywhere in the world.
- It is the investigational compound retatrutide (development code LY3437943), a triple GIP/GLP-1/glucagon receptor agonist being developed by Eli Lilly and Company, currently available only to people enrolled in Lilly's registered clinical trials.
- The Phase 3 TRIUMPH programme is studying once-weekly subcutaneous retatrutide for chronic weight management in adults with obesity or overweight, for type 2 diabetes with excess weight (TRIUMPH-2), and for obesity with established cardiovascular disease (TRIUMPH-3).
- Eli Lilly has stated it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027.
- No regulatory authority has approved retatrutide for prescription use, and no approved brand name, strength or pack presentation exists yet, so this text describes trial findings only and is not prescribing information for a marketed product.
Side Effects
- In Eli Lilly's published Phase 2 and Phase 3 trials, the most frequently reported effects with investigational retatrutide were gastrointestinal: nausea (reported by more than 4 in 10 participants at the highest studied dose), vomiting, diarrhoea, constipation and reduced appetite, most described as mild to moderate and occurring mainly while the dose was being increased.
- Injection-site reactions have also been reported.
- A notable finding was dysesthesia, an abnormal tingling or burning skin sensation, seen in up to around 1 in 8 participants on the highest dose compared with fewer than 1 in 100 on placebo.
- Because retatrutide has no finalised, FDA-approved prescribing information, there is no confirmed boxed warning and no complete list of serious risks; trial participants are monitored closely by their study site and should report severe abdominal pain, persistent vomiting or signs of gallbladder problems immediately.
Precautions & Warnings
- Because retatrutide remains investigational, no confirmed contraindications, pregnancy category or full safety profile has been established outside clinical-trial protocols.
- As with other medicines in the GIP/GLP-1/glucagon receptor agonist class, Lilly's trial protocols exclude people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and participants are monitored for pancreatitis, gallbladder disease, and low blood sugar (hypoglycaemia) when retatrutide is used together with insulin or a sulfonylurea.
- Retatrutide is given only by subcutaneous injection under investigator supervision within a study, never for home self-treatment outside a trial.
- Anyone interested in retatrutide should access it only through a registered clinical trial, not through unregulated compounded or grey-market products sold online, which carry unknown purity, strength and safety risks.
Avoid Interactions
- No formal drug-interaction studies for retatrutide have been completed or published, because it remains an unapproved investigational molecule with no finalised label.
- Within clinical trials, as with related GIP/GLP-1 receptor agonists, retatrutide slows stomach emptying and so may reduce or delay the absorption of oral medicines taken around the same time, and combining it with insulin or a sulfonylurea may increase the risk of hypoglycaemia, requiring dose adjustment by the study team.
- Trial participants must disclose all prescription medicines, over-the-counter products, herbal remedies and supplements to their study team before and throughout treatment.
- Until an FDA-approved label exists, no complete interaction list can be given, and retatrutide should never be combined with other weight-loss or diabetes medicines outside a supervised trial protocol.
References
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial - Eli Lilly Investor Relations
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials - Eli Lilly Investor Relations
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) - Lilly Trials Registry
Frequently Asked Questions
No. Retatrutide (Investigational) is not approved anywhere; it is investigational retatrutide, a triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly, studied in Phase 3 TRIUMPH trials for obesity, type 2 diabetes, and obesity with cardiovascular disease. Lilly plans to file for US approval in early 2027. It is available only inside registered clinical trials.
In Lilly's trials, retatrutide is given as a once-weekly subcutaneous injection, with the dose raised gradually over months to limit stomach side effects. It has no approved label, so dosing, frequency and injection technique are set by the trial protocol and study team, not by a pharmacy prescription.
The most common effects reported with retatrutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation and reduced appetite, usually mild to moderate during dose increases. Some participants reported dysesthesia, an unusual tingling or burning skin sensation. Report severe abdominal pain, persistent vomiting or possible gallbladder symptoms to your trial team right away.
Participants should avoid starting new prescription or over-the-counter medicines, herbal supplements, or other weight-loss or diabetes drugs without telling the study team, since retatrutide slows stomach emptying and can change how other drugs are absorbed. Alcohol and any compounded 'retatrutide' bought outside a trial should also be avoided.
No. Retatrutide is not licensed for sale or prescription anywhere, so any product sold online or by a compounding pharmacy as retatrutide is not the tested, FDA-reviewed formulation and carries unknown purity and strength. The only verified way to access it is by enrolling in a registered Eli Lilly clinical trial.
Eli Lilly is studying retatrutide in Phase 3 trials for chronic weight management in adults with obesity or overweight, for type 2 diabetes, and for obesity in people with established cardiovascular disease. All trials are ongoing or recently completed; no approval date is confirmed, and a US filing is not planned before 2027.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
